{"id":"coppebvcad-vs-beacopp-vs-abvd","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Pulmonary toxicity"},{"rate":null,"effect":"Infertility"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These are polychemotherapy regimens used in lymphoma treatment. ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) are established Hodgkin lymphoma treatments. COPPEBVCAD appears to be a variant combining elements of these regimens. They work through multiple mechanisms including DNA alkylation, topoisomerase inhibition, and microtubule disruption.","oneSentence":"COPPEBVCAD, BEACOPP, and ABVD are combination chemotherapy regimens that use multiple cytotoxic agents to kill rapidly dividing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:42.122Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin lymphoma (early-stage and advanced-stage)"}]},"trialDetails":[{"nctId":"NCT00443677","phase":"PHASE3","title":"Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)","status":"COMPLETED","sponsor":"Gruppo Italiano Studio Linfomi","startDate":"2000-04","conditions":"Advanced Hodgkin Disease","enrollment":307}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"COPPEBVCAD vs BEACOPP vs ABVD","genericName":"COPPEBVCAD vs BEACOPP vs ABVD","companyName":"Gruppo Italiano Studio Linfomi","companyId":"gruppo-italiano-studio-linfomi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"COPPEBVCAD, BEACOPP, and ABVD are combination chemotherapy regimens that use multiple cytotoxic agents to kill rapidly dividing cancer cells. Used for Hodgkin lymphoma (early-stage and advanced-stage).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}